Back
No Against Vygon India in Medical Consumables Antitrust Dispute: CCI
The (CCI) has closed an antitrust complaint against medical device company , ruling that the allegations of and did not make out a . The order, passed by a bench comprising Chairperson Ravneet Kaur and Members Sweta Kakkad and Deepak Anurag, concludes that the informant failed to establish that Vygon holds a or that its distribution agreement causes an .
The Dealership Dispute
The case was initiated by , a Gujarat-based partnership firm that served as Vygon’s non-exclusive dealer from 2012 until it voluntarily terminated the dealership in . Vibrant had previously been an employee of Vygon between 2005 and 2012.
Vibrant alleged that Vygon’s Master Dealership Agreement (MDA) contained , including , prohibitions on participating in certain tenders, , , mandatory 45-day stocking requirements, intrusive audit powers, and the supply of expired or about-to-expire products. The informant claimed these practices violated Section 3(4) () and Section 4 () of the .
The Battle Over
A critical point of contention was how to define the . Vibrant argued that the market should be limited to neonatal and paediatric vascular access devices and specialty critical-care catheters used in tertiary care hospitals, where it claimed Vygon enjoyed a 40-70% market share and was often the sole bidder in tenders.
Vygon countered that the MDA covered over 800 products, making it inappropriate to focus narrowly on catheters. It proposed a broader market for supply of medical consumables to institutional buyers, or, alternatively, the market for sale and distribution of catheters. Citing an report, Vygon argued that its market share was negligible in both scenarios, with numerous domestic and international competitors such as , , , , and operating in the space.
No Dominance, No Adverse Effect
The Commission sided with Vygon on the market definition issue, noting that the allegations extended across Vygon’s entire product portfolio, warranting a . It observed that “it would not be appropriate to assess the entire impugned distribution arrangement solely in the market for neonatal PICCs, as suggested by the Informant.”
On dominance, the CCI found that Vibrant had not produced evidence of Vygon’s market share. The information available in the public domain, including the EY report, indicated that competitors possessed substantial financial and production capabilities, undermining any claim of dominance. “The competitive position of rival suppliers does not suggest that the OP enjoys a in any of these markets,” the Commission stated.
Turning to , the CCI emphasised that for an agreement to cause an , the entity must hold some degree of . The absence of such power made of competing suppliers or dealers unlikely. Crucially, the Commission noted that after its relationship with Vygon ended, Vibrant had obtained a dealership with , demonstrating that switching to an alternative supplier was not prohibitive.
The Final Order
Based on the available material, the Commission concluded: “It can neither be said that the OP enjoys a for the purposes of Section 4 of the Act nor that the impugned vertical restrictions have caused, or are capable of causing, under Section 3(4) of the Act.”
The information was closed forthwith under . The CCI also granted confidentiality to certain documents filed by Vygon under , for a period of three years.
Key Observations from the Judgment
- “For an assessment under Section 3(4) of the Act, the impugned conduct is required to be examined with reference to the market in which the alleged vertical agreement or restraint operates along with its likely or actual effect on competition therein.”
- “A vertical restriction may contravene Section 3(4) of the Act, if it causes or is likely to cause as per Section 19(3) of the Act. The entity concerned must enjoy some degree of for to materially foreclose the competition.”
- “In the instant matter, absence of the of the OP, as examined above, makes of competing suppliers or dealers unlikely.”
Broader CCI Context
The decision comes amid a period of active antitrust scrutiny in India. In a separate matter, the CCI recently closed its inquiry against Google following a complaint by , after the enactment of the fundamentally altered the regulatory landscape. While that case turned on , the Vygon order reaffirms the Commission’s insistence on rigorous for establishing dominance and competitive harm.
